ArticleScientific reports2025
Constructing a sixteen lactate-related gene risk signature for LUAD to predict the prognosis and TME by machine learning.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Although it is the most common subtype of lung cancer in clinical practice, lung adenocarcinoma (LUAD) was proven to be associated with a poor prognosis. In recent years, lactate metabolism has been considered an important biological mechanism in lung cancer. However, the mechanisms of lactate-related genes in tumour microenvironment (TME) of LUAD are unknown. Lactate-related genes modification patterns in 701 LUAD samples from TCGA and GEO database were systematically assessed on the basis of 16 lactate-related genes (LRGs).We also identified the correlation of these clusters to the TME and immune cell infiltration in the TME. After unsupervised clustering analysis was performed, the LUAD samples were divided into three lactate-related gene phenotypes on the basis of 36 prognostic lactate-related genes (PLRGs). These molecular subtypes have different immune cell infiltration characteristics and pathway enrichment. Using LASSO, a 16-LRG risk signature was constructed. The lactate-related signature demonstrated a stable and accurate ability to predict the prognosis of LUAD in patients. Furthermore, the lactate-related signature demonstrated good predictive ability for immune infiltrating cells, tumour mutation burden, and response to immunotherapy. The 16-LRG risk signature was subsequently verified in the GSE50081 GEO cohort. This study revealed the significant clinical utility of the 16-LRG risk signature in the understanding the TME and prognosis of LUAD. The 16-LRG risk signature is conducive to understanding immune cell infiltration in the LUAD TME and contributes to the selection of more effective immunotherapy strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.